Overnight Market report, page-666

Thanx for sharing the article tankhexman, let’s hope that it’s EFTI that is potentially chosen to help extend Keytrudas patent among the many that are currently being trialed . As far as lung and head neck cancer go EFT in IO/IO treatment going from the data and management, appears to be working as well as any ,with minimal safety issues, and great margins due to its form of administration.That’s not to say something better may be developed in the future, but for now it appears to be as successful as any, therefore you could presume it would be closely being monitored by Merck.
Next box to tick would be fast track approval in 1st line lung cancer, which potentially may be just round the corner.Whilst the company continues to tick the boxes, the competitive tension builds , hopefully eventuating in a favourable licensing deal with one of the big pharmas.